1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC — Masafumi Ikeda (2020) | RDL Network
Masatoshi Kudo, Masafumi Ikeda, Andrew X. Zhu, S. Qin, Tae‐Yop Kim, Ho Yeong Lim, В. В. Бредер, P. Merle, Ahmed S. Kaseb, D. Li, N. Ma, M. Villalobos, S Stanzel, Vincent E. Gaillard, Xu Dz, S. Hernandez, Ann‐Lii Cheng, RS Finn, Peter R. Galle, Michel Ducreux
Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, Ho Yeong Lim, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Yin‐Hsun Feng, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Andrew X. Zhu, Ann‐Lii Cheng
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn
Discussion(0)
No comments yet. Be the first to comment.